Clinical trials
Metastatic Solid Tumor clinical trials
Below are recruiting metastatic solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,098 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06500819RecruitingPhase 1
B7-H3 CAR T cells for relapsed solid tumors
This trial tests a new immune therapy using your own cells (called B7-H3 CAR T cells) to treat solid tumors that haven't responded to other treatments. It may help children and young adults with certain cancers that are hard to cure.
Palo Alto, CaliforniaAges 2–30 - NCT07174453RecruitingPhase 3
Comparing side effects of different doses of immunotherapy
This study compares standard dosing schedules of pembrolizumab or nivolumab (two immunotherapy drugs) to see which one causes fewer immune-related side effects. It is for people with solid tumors who are already eligible to receive one of these drugs as part of their standard care.
Westwood, KansasAges 18 years+ - NCT07179692RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a type of immunotherapy called CAR-T, which is designed to recognize and attack cancer cells that have a protein called CEA on their surface. It's for people with advanced cancers like colorectal, esophageal, gastric, pancreatic, lung, or bile duct cancer who have tried at least two standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07121036RecruitingPhase 1
High-dose vitamin C infusion for advanced solid tumors
This trial tests a special high-dose vitamin C infusion, given based on how your body processes it, for people with advanced solid tumors. It aims to see if this vitamin C therapy can be safely combined with your current or new chemotherapy to help control the cancer.
Wuhan, HubeiAges 18–75 - NCT07581912RecruitingPhase 2
Fulzerasib Plus Cetuximab for Advanced Colorectal Cancer With KRAS G12C
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
Hangzhou, ZhejiangAges 18–85 - NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07006727RecruitingPhase 1
Study of a new drug for advanced DLL3-positive solid tumors
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
Iowa City, IowaAges 18–100 - NCT06551142RecruitingPhase 1
Study of GSK5764227 for advanced solid tumors
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
Stanford, CaliforniaAges 18 years+ - NCT06979596RecruitingPhase 2
A study of MK-5684 for certain solid tumors
This trial tests an investigational drug called MK-5684 for people with specific types of breast, ovarian, or endometrial cancer. It aims to see if this treatment can help shrink or control the cancer when standard treatments have stopped working or are no longer effective.
Anchorage, AlaskaAges 18 years+ - NCT06971523RecruitingPhase 1/Phase 2
Study of CTS3497 for cancers missing a specific protein
This trial tests a new drug called CTS3497 in people whose tumors lack a protein called MTAP. The drug aims to stop cancer cells from growing by targeting a weakness caused by this missing protein.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06956690RecruitingPhase 1/Phase 2
Testing HMBD-501 for HER3-positive advanced solid tumors
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06947811RecruitingPhase 1/Phase 2
Almonertinib plus Palbociclib for KRAS-mutated solid tumors
This trial tests a combination of two targeted drugs, Almonertinib and Palbociclib, for people with advanced solid tumors that have a KRAS mutation. It aims to see if this new combination can shrink tumors or slow their growth, and it may be an option if your cancer has not responded to other treatments.
Guangzhou, GuangdongAges 18–70 - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Los Angeles, CaliforniaAges 1 month–17 years - NCT06902350RecruitingPhase 1
Experimental drug CS231295 for advanced solid tumors
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06885697RecruitingPhase 1
CAR T-cell therapy for mesothelioma and other solid tumors
This study tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack cancer cells with a protein called mesothelin on their surface. It may help people with mesothelioma or other solid tumors that have not improved with standard treatments.
Bethesda, MarylandAges 18–120 - NCT06884618RecruitingPhase 1
Study of a new drug for advanced solid tumors with RAS mutations
This trial is testing an experimental drug for people whose cancer has spread and has a specific gene change called RAS. The study aims to see if the drug is safe and helps shrink tumors.
Duarte, CaliforniaAges 18 years+ - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06824155RecruitingEarly Phase 1
Targeted radiation for HER2-positive advanced cancers
This trial tests a new drug that delivers radiation directly to cancer cells that have a specific marker called HER2. It may be an option for patients whose cancer has grown despite other treatments.
Kingswood, New South WalesAges 18 years+ - NCT06821503RecruitingPhase 1/Phase 2
Study of LM-108 with chemo for advanced pancreatic cancer
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07439120RecruitingEarly Phase 1
Testing a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
ShanghaiAges 18 years+ - NCT06795022RecruitingPhase 1/Phase 2
Testing AZD9793 for advanced solid tumors with GPC3
This trial is testing a new medicine, AZD9793, for people with advanced or metastatic solid tumors that have a specific marker called GPC3. The goal is to see if AZD9793 can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06796907RecruitingPhase 1/Phase 2
Mocertatug rezetecan with other drugs for advanced solid tumors
This trial tests a new drug, mocertatug rezetecan, combined with other anti-cancer therapies for people with advanced solid tumors like endometrial or ovarian cancer. It aims to see if the combination is safe and effective.
La Jolla, CaliforniaAges 18 years+
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic solid tumor?
- Yes. Clin2 currently lists 1,098 recruiting metastatic solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.